The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
Not every company in biotech land is loved by investors. In fact, many biotechs top the list of companies with high short interest as a percentage of float.
As of the end of February, Myriad Genetics was the second-most shorted company as a percentage of float. Sarepta Therapeutics came in at No. 9. OncoMed Pharmaceuticals , VIVUS , and MannKind rounded out the top five most-shorted biotechs.
In the slideshow below, you can see their metrics and reasons why some investors don't like them.
Fear not if your favorite biotech makes the list; Questcor Pharmaceuticals and Ziopharm Oncology, which were in last month's list, fell back in favor -- at least somewhat -- dropping off the top-five list.
A stock pick our chief investment officer loves
While it's true that a highly shorted stock can make you money in a short squeeze, you still have to be confident that other's will buy the stock. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind originally appeared on Fool.com.Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.